Fujirebio said Health Canada has approved two of its blood-based neurological health diagnostics for clinical use, both cleared to run on the company’s automated Lumipulse G platform. The agency issued a Class II Medical Device license for Lumipulse G NfL, which quantifies neurofilament light chain (NfL), a neuroaxonal injury biomarker with promise in multiple sclerosis. Health Canada also granted clearance for the Lumipulse G pTau 217 plasma assay, used to help differentiate Alzheimer’s-linked neurodegeneration from other causes. Fujirebio noted both assays received CE marking earlier this year, with NfL clearance in March and pTau 217 clearance in May. The approvals matter because blood-based biomarkers are increasingly positioned as scalable alternatives to more complex imaging and cerebrospinal fluid testing, and the Lumipulse G platform can support broader point-of-care and lab automation workflows.